



Sero-Surveillance and Risk Factors of Hepatitis B Virus among Pregnant Women in Sokoto, North-Western Nigeria

Alkali Bello Rabi¹, Ottah Chidinma May², Shuaibu Abdulmalik Bello^{1*},
Abubakar Firdausi Ibrahim², Audu Musa³, Aisha Bello² and Bello Mukhtar²

¹Faculty of Veterinary Medicine, Usmanu DanFodiyo University, Sokoto, Nigeria.

²Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Nigeria.

³Ministry of Agriculture and Natural Resources, Damaturu, Yobe State, Nigeria.

Authors' contributions

This work was carried out in collaboration between all authors. Author ABR designed the study. Authors ABR and SAB performed the statistical analysis. Authors SAB and OCM wrote the protocol, and wrote the first draft of the manuscript. Authors SAB and BM managed the analyses of the study. Author AM managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/ISRR/2018/38992

Editor(s):

- (1) Tulay Okman-Kilic, Department of Obstetrics and Gynecology, Trakya University, Turkey.
- (2) Basavraj S. Nagoba, Professor, Department of Medical Education, MIMS Medical College, India.
- (3) Kailash Gupta, Division of AIDS, NIAID, NIH, USA.

Reviewers:

- (1) Rehab Abd Elfattah Mohammed Omran, Al Azher University, Egypt.
- (2) Oti Baba Victor, Nasarawa State University, Nigeria.

Complete Peer review History: <http://www.sciencedomain.org/review-history/23968>

Original Research Article

Received 24th December 2017
Accepted 16th March 2018
Published 4th April 2018

ABSTRACT

Background: Maternal infection with Hepatitis B virus (HBV) can lead to chronic infection in the neonate, and the risk depends on her status of Hepatitis B surface antigen (HBsAg) and Hepatitis B e antigen (HBeAg). This study aimed at determining the sero-surveillance of HBV among pregnant women in Sokoto, Nigeria. Blood samples from 93 pregnant women were tested for the HBV using Immunochromatographic Methods (Aria, USA) and seropositive samples evaluated for TNF-alpha and ALT. Questionnaires were administered to get socio-demographic information.

Statistical Analysis: SPSS © statistical software.

Results: The HBV seroprevalence was 17.2% for HBsAg.

Conclusions: The seroprevalence of HBsAg was 17.2%. Elevated TNF-alpha level and ALT level were associated with HBV infection. Therefore, screening of pregnant women for Hepatitis B is necessary to identify the neonates at risk.

*Corresponding author: Email: abdulmalik.shuaibu@udusok.edu.ng;

Keywords: *Hepatitis B virus; hepatitis B surface antigen; hepatitis B surface antibody.*

1. INTRODUCTION

HBV belongs to the family Hepadnaviridae and along with HCV are the only oncogenic hepatitis viruses. It is a common cause of acute and chronic liver disease worldwide [1]. It is transmitted through contact with the blood or other body fluids of an infected person [1]. It is endemic in Sub-Saharan Africa including Nigeria [2] and vertical transmission is a major mode of transmission [3]; therefore, prevention of mother to child transmission is an essential step in reducing the global burden of chronic HBV [3].

The liver is an essential site of synthesis of cytokines and major clearance organ for various cytokines [4]. Hepatitis causes a hepatic inflammatory illness characterised by mononuclear and polymorphonuclear cellular infiltrates with evidence of hepatic macrophage activation [5]. Tumour necrosis factor (TNF- α) is a principal mediator of inflammation and cellular immune responses with multiple biological functions, including cytotoxicity towards tumour cells and virus-infected cells, several immunomodulatory actions and initiation of the inflammatory response [4]. It is a proinflammatory cytokine released mainly from monocytes and lymphocytes in response to inflammatory stimuli. TNF- α is an important proinflammatory cytokine in the host defence mechanism against many intracellular pathogens [5]. It suppresses HBV replication and promotes its eradication by stimulating HBV-specific cytotoxic T-cell response [5]. The production of TNF- α by mononuclear cells is thought to be increased in patients with chronic liver disease [4]. Persistent viral hepatitis infection results in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC).

Liver cell injury or necrosis is measured by determining alanine aminotransferase (ALT) levels [6]. During normal pregnancy serum alanine aminotransferase activity level remains within the normal limits established for non-pregnant women [7]. Therefore, measurement of serum aminotransferase levels thus remains the most useful test for the routine diagnosis of liver diseases during pregnancy [8]. Measurement of serum alanine aminotransferase (ALT) activity level is the most useful test for the diagnosis of liver diseases such as viral hepatitis. Serum ALT activity values above the reasonable upper limit should be considered pathologic and should lead

to further investigations [9]. Thus, when viral hepatitis or liver disease is clinically suspected in a pregnant woman, any increase in serum ALT activity levels should be considered pathologic and should prompt further evaluation.

Viral hepatitis is the most common cause of jaundice in pregnancy [10]. Viral hepatitis B in pregnancy is associated with high risk of maternal, fetal, and neonatal complications [11]. Acute hepatitis in pregnancy has been shown to induce premature labour and prematurity with its attendant effects [11,12]. According to [12], studies have shown an increase in the incidence of prematurity over that seen in the general population with a higher risk of intra-ventricular haemorrhage as well, which was probably related to the higher incidence of preterm delivery. Maternal infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can expose the fetus/newborn to a subsequent chronic hepatitis infection [13]. However, perinatally acquired HBV is a largely preventable condition [14]. The risk of vertical transmission depends on the time at which the pregnant woman acquired HBV infection, and on her statuses of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Without prophylaxis, the risk of perinatal HBV infection in an infant with an HBsAg positive mother is less than 10% if the mother's HBeAg status is negative.

Screening for HBV is routine in pregnancy in most developed countries of the world. It is a recommendation by most of the 122 Colleges of Obstetrics and Gynecology all over the world to screen pregnant women for HBV routinely in pregnancy [12], however, in Nigeria, screening of antenatal women for HBV and HCV is not a routine practice [12]. Also, routine vaccination of newborns is not widely available in low resource settings in Nigeria. Even though Nigeria approved the inclusion of HBV in its National Program on Immunization (NPI) in 1995, the vaccine only became widely available in 2004 [15]. Despite the fact that the vaccine had been made available via the NPI, immunisation coverage for Hepatitis B is still not optimal.

HBV infection leads to liver cell injury, resulting in elevated TNF-alpha and ALT levels which also results in complications in both mother and foetus and it has also been shown that women with a history of preeclampsia are at an increased risk for developing cardiovascular

diseases [16;17]. Screening pregnant women can give a reliable prevalence of the disease in a population and provide an avenue for preventing MTCT virus [12].

1.1 Objective of the Study

The objective of this study is to determine the prevalence of Hepatitis B virus infection in pregnant women.

Specific Objectives of the Study

1. Determine the prevalence of hepatitis B among pregnant women in Sokoto, North-Western Nigeria.
2. To determine TNF-alpha and Alanine transaminase (ALT) concentration among infected and non-infected pregnant women.
3. To evaluate the risk factors associated with HBV infection among pregnant women in Sokoto.

2. MATERIALS AND METHODS

2.1 Study Area

The study was conducted in Specialist Hospital, Sokoto metropolis, Sokoto State, Northwestern Nigeria. This hospital services rural communities from all parts of the state, including neighbouring states. Sokoto state lies between longitude 11030' to 13050' East and latitude 40 to 6' North and is bound with the Republic of Niger to the North, Kebbi State to the West and South, and Zamfara to the South and East. Sokoto is in the dry Sahel geographical region of Nigeria, surrounded by sandy savannah and isolated hills with an annual average temperature of 28.3°C, on the whole, a very hot area. The warmest months are February to April when daytime temperatures can exceed 45°C [18]. The rainy season is from June to October during which showers are a daily occurrence. The showers rarely last long and are a far cry from the regular torrential rain known in wet tropical regions. From late October to February, during the cold season, the climate is dominated by the Harmattan wind blowing, Sahara dust over the land, the dust dims the sunlight thereby lowering temperatures significantly and also leading to the inconvenience of dust. The total population and annual growth rate stood at 3.7 million and 3.0% respectively in the 2006 national population census [19].

2.2 Study Design

The study was a purposive study for detection of serum HBV among pregnant women, and TNF-alpha and ALT determination in infected patients. Consecutive random sampling technique was used to select participants, and semi-structured close/open-ended questionnaire administered prior to sample collection until the desired sample size was obtained.

2.3 Sampling Method

The study was a cross-sectional survey among pregnant women attending ANC in the specialist hospital out from September to October 2017. A random sampling technique was adopted and the subjects recruited until the desired sample size was obtained. This sampling technique provided the opportunity for the realistic generalisation of the research population [20]. A questionnaire based on WHO generic protocol (Appendix I) was adopted and administered to generate the primary data where adequate information on every participant was obtained. Patient information such as identification number, address, socio-economic status was collected. The validity of the questionnaire was determined by the critique of research experts. The modification of the questionnaire was based on the experts' comments and advice. The reliability of the questionnaire was determined through the administration of the modified copy to some pregnant women in the hospital selected for the study. The results provided the basis for the final modification of the questionnaire.

2.4 Sample Collection

Blood samples were collected from consenting pregnant women attending ANC in Specialist Hospital, Sokoto. Three milliliter (3 ml) of venous blood samples were collected aseptically using a sterile vacutainer, blood specimen bottle, holder, and needle, from each subject into a sterile plain vacutainer blood specimen bottles, adequately labelled (patient ID and date of collection) and allowed to clot at room temperature (220C). After clotting, it was centrifuged at 3000 rpm for 5 minutes to obtain a clear unhaemolyzed serum. The serum samples were separated using clean Pasteur pipettes into sterile Eppendorf tubes and stored at -20°C in Central Research Laboratory, City Campus, Usmanu Danfodiyo University, Sokoto until analysed. Haemolytic, icteric or lipaemic specimens were not used. A serum specimen logbook was kept in the laboratory where information on all pregnant women was

checked regularly and matched with the information in the questionnaire to ensure proper entry of information.

2.5 Ethical Considerations

Due ethical approval was obtained from the State Ministry of Health and from the ethical committee of the Specialist Hospital, Sokoto.

2.5.1 Inclusion criteria

Pregnant women attending ANC in Sokoto metropolis who have given their informed consent will be eligible to participate.

2.5.2 Exclusion criteria

Pregnant women who did not give their consent will be excluded from this study.

2.5.3 Questionnaire administration

A semi-structured close/ open-ended questionnaire will be developed and tested for validity and reliability and subsequently administered to subjects.

2.6 Sample Size Estimation

The sample size was calculated at 6.51% prevalence, [2] at 95% confidence interval, with desired precision of 5%, using the formula.

$$n = (Z^2Pq) / d^2 [21]$$

The calculated sample size was 93.

2.7 Determination of HBV Profile Using Immunochromatographic Method (Aria, Usa)

A commercial Aria *HBV-5 Panel Rapid Test Kit* was used to detect the HB profile algorithm (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) in serum samples collected according to manufacturer's instructions. The *Aria HBV 5-Parameter Rapid Test* for the qualitative detection of HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in human serum or plasma.

The serum samples were analyzed for the in-vitro quantitative determination of Human Tumor Necrotic Factor concentrations using a commercially obtainable Enzyme Immunoassay (ELISA) kit from WKEA™, China.

Alanine transaminase (ALT) is a transaminase enzyme. It is also called serum glutamic pyruvic transaminase (SGPT) or alanine aminotransferase. (ALT) is found in serum and in various bodily tissues, but is usually associated with the liver. The serum samples were estimated for the level of ALT using colorimetric method (Endpoint) (Randox Switzerland™), obtained from the manufacturer. The assay was carried out according to the manufacturer's instructions, and it was ensured that the same incubation time was maintained for all samples.

2.8 Data Analysis

Data obtained and recorded during sampling and laboratory findings were entered and stored in MS-Excel. The data were subjected to statistical analysis using the Statistical Package for Social Sciences (SPSS) version 20 (Inc., Chicago, IL, USA). Data were represented using descriptive statistics and presented using percentages. Chi square analysis was used to determine the association between the infections and variables socio demographic variables. Independent sample t-test was used to make comparison between the mean ALT levels and TNF-alpha level of HEV Infected and non-infected patients. P-value of less than or equal to ($P \leq 0.05$) was regarded as statistically significant.

3. RESULTS

Sero-surveillance studies showed that pregnant women had a high positive rate of HBV at 17.2% (16/93) as shown in Table 1.

3.1 TNF-Alpha and ALT Levels in HBV Infection among Pregnant Women in Sokoto, North-Western Nigeria

TNF-alpha levels and ALT levels were evaluated among seropositive samples and it was observed that samples that tested positive had significantly high TNF-alpha level compared to uninfected control. Independent sample t test showed statistical significance with p-value less than 0.05 at 95% CI as shown in Table 2.

4. DISCUSSION

The overall prevalence of HBV positivity, indicated by the presence of HBsAg was 17.2% (16/93).

Table 1. Sero-surveillance of HBV Infection among Pregnant Women in Sokoto, North-Western Nigeria

Viral Hepatitis	Positive	Negative	Total	Prevalence (Percentage %)
HBV	16	77	93	17.2

Table 2. Mean ALT and TNF-alpha levels among HBV Infected Pregnant women and Uninfected Pregnant Women in Sokoto, North-Western Nigeria

Groups:		TNF-alpha	ALT
Non-infected Pregnant women		6.08 ± 0.558	6.23 ± 0.414
P-value:	HBV Infected Pregnant women	30.21 ± 3.088	14.34 ± 1.017
		0.026	0.00

Values are Mean ± SEM, n= Number of subjects, ALT= Alanine Transaminase, TNF-ALPHA= Tumor Necrotic Factor - Alpha, P value < 0.05 is considered as statistically significant.

Table 3. Socio-demographic pattern of HBV among pregnant women in Sokoto, North-Western Nigeria (n=93)

Parameter	Level	HBV status		Df	Chi-value	P-value at 95% CI
		Negative (%)	Positive (%)			
Age group (years)	18-25	59 (79.7)	15 (20.3)	2	0.00	1.000
	26-35	13 (100)	0 (0)			
	36-54	5 (83.1)	1 (16.7)			
Type of family	Monogamous	65 (87.3)	9 (12.7)	1	0.00	1.000
	Polygamous	12 (63.2)	7 (36.8)			
Location	Urban	33 (91.7)	3 (8.3)	1	0.00	1.000
	Rural	23 (63.9)	13 (36.1)			
Educational	Non-Formal	40 (81.7)	9 (18.3)	2	0.00	1.000
	Primary	18 (85.7)	3 (14.3)			
	Tertiary	6 (85.7)	1 (14.3)			
Employment status	House wife	62 (80.2)	15 (19.8)	3	0.25	0.9696
	Civil servant	6 (100)	0 (0)			
	Business	10 (90.9)	1 (9.1)			
Gestational stage	1 st Trimester	0 (0)	0 (0)	2	0.00	1.000
	2 nd Trimester	22 (75.9)	7 (24.1)			
	3 rd Trimester	55 (85.9)	9 (14.1)			
Parity	Primiparous	10 (90.9)	1 (9.1)	1	0.00	1.000
	Multiparous	67 (81.7)	15 (18.3)			

The 17.2% prevalence of HBsAg among pregnant women in Sokoto is similar to a report of [22] with a prevalence of 17.2% among pregnant women in Bayara Bauchi, [23] and with a prevalence range from 2-15% [12]. However, it is higher than 12.6% in Plateau State [24] 12.3% in Minna [25], 9.3% in Awka, [26], 8.3% in Nnewi, [12] and 4.6% in Enugu [27]. However, it is lower than the 23.3% report of [28] in Kano. This goes to show that despite the endemicity of HBV in Nigeria, there is a higher prevalence in Northern Nigeria, compared to the South. Prevalence of HBV in this study shows endemicity of the infection according to WHO criteria [29].

The HBV prevalence of 17.2% seen in this study is higher when compared to the 6.51% reported in an earlier study by [2] among pregnant women

in Sokoto. This varying reports from Sokoto are similar to the reports from Benin City where [30] documented a high prevalence of 12.5% and [31] reported a low prevalence of 2.2% among pregnant women in the same Benin City. This implies that prevalence may vary in similar geographic locality nonetheless, the explanations for such may be due to the sample size.

On the basis of age, the age group 18-25 has the highest rate of infection of 20.3%, similar to studies conducted by [2]. Other variables such as occupation, level of education, trimester of pregnancy and knowledge of HBV were evaluated with highest percentages among non-formally educated women, housewives and those without knowledge of hepatitis. The gestational stage of the pregnancy showed a higher

Table 4. HBV knowledge attitude and practice among pregnant women in Sokoto, North-Western Nigeria

Variables	HBV status		HBV status		Df	Chi-value	P-value at 95% CI
	Positive	(%)	Negative	(%)			
Surgery							
Yes	2	(16.7)	10	(83.3)	1	0.00	1.000
No	14	(17.3)	67	(82.7)			
Blood transfusion							
Yes	3	(11.1)	5	(89.9)	1	0.00	1.000
No	13	(15.1)	72	(84.7)			
Sharing sharp objects							
Yes	3	(17.6)	14	(82.4)	1	0.00	1.000
No	13	(17.1)	63	(82.9)			
Knowledge							
Yes	1	(11.1)	8	(88.9)	1	0.00	1.000
No	15	(17.9)	69	(82.1)			
Is there vaccine							
Yes	0	(0)	2	(100)	1	0.00	1.000
No	16	(17.5)	75	(82.5)			

prevalence, though not statistically significant in the second trimester with 24.1% and this is similar to the record of the highest prevalence in the second trimester of pregnancy of 13.4% by [25] and 11.3% by [24] in Plateau State.

Changes in Liver enzymes in the study conducted by [32] showed that Liver function tests are used to determine if the liver has been damaged or its function impaired. Elevations of certain liver tests in relation to others aids in that determination. The aminotransferases (which include ALT and AST) are notably elevated in liver damage caused by liver cell disease (hepatocellular disease). Alanine aminotransferase (ALT), Pregnant women screened in this study recorded 26.3% Abnormality in ALT levels which have been correlated positively with liver inflammation, while patients with persistently normal ALT levels had significantly lower liver damage compared with patients with either intermittent or persistently elevated ALT Levels [33]. Therefore measurement of aminotransferase levels by serial observations and analysis remain the most common and convenient way to identify liver inflammation in patients particularly with chronic HBV infection.

It was also observed that samples that tested positive had significantly high mean ALT level of 14.34. Independent sample t-test showed statistical significance (P-value = 0.015, CI=95%) as shown in Table 2, indicating an association between ALT and Hepatitis. This corresponds to [34] where raised serum ALT activity was found in

HBV infections in Tawian, and research by [35], who also found significantly raised ALT levels in HBV in Kaohsiung, Taiwan. Chi square analysis showed no statistical significance between ALT levels in HBV Infection among Pregnant Women in Sokoto, North-Western Nigeria, at 95% CI (P-value>0.05: $\chi^2 = 0.00$, P-value = 1.0000).

HBV induces TNF- α expression in human liver and human hepatoma cell lines [36] and patients with chronic hepatitis have elevated plasma TNF- α levels, and their peripheral blood mononuclear cells show enhanced TNF- α production in vitro [37].

In this study, it was observed that samples that tested positive had significantly high mean TNF-alpha level of 30.21. Independent sample t-test showed statistical significance (P-value < 0.029, CI=95%) indicating an association between TNF-alpha and viral hepatitis. This is similar to [38] where statistical analysis revealed highly significant increase in the mean value of serum TNF- α in patients with viral liver diseases. It is also similar to findings by [39], that serum level of TNF- α increases significantly in liver diseases, and this agrees with research by [40] that TNF- α levels were increased both in serums and liver tissues of patients with Hepatitis B. [41] reported increased serum concentrations of soluble TNF-alpha receptors in persons with viral hepatitis and liver disease, and this agrees with [42] that serum levels of soluble TNF- α receptors are significantly elevated in chronic hepatitis infection.

Sabry et al. [38] proposed that high serum level of TNF- α is a key mediator in the pathogenesis of liver necrosis and serum level of TNF- α reflects progression of inflammation, therefore, increased TNF- α in HBV contribute to role of innate immunity in stimulating the adaptive immune responses, thus signifying the role of TNF- α in antibody production. Chi square analysis showed no statistical significance between TNF-alpha levels in HBV (HBSAg) infection among Pregnant Women in Sokoto, North-Western Nigeria, at 95% CI (P-value > 0.05: $\chi^2 = 0.01$, P-value = 0.9350).

Though TNF-alpha and ALT values were significantly elevated in seropositive patients, Spearman Rho analysis showed no association between TNF-alpha and ALT level in HBV infection.

5. CONCLUSION AND RECOMMENDATIONS

The outcome of this study provides evidence that pregnant women are exposed to HBV infection. Findings also showed that TNF-alpha and ALT values were significantly elevated in seropositive patients, however, Spearman Rho analysis showed no association between TNF-alpha and ALT level in HBV infection.

Sensitization and Public enlightenment should be advocated to lower the burden of the disease among the study population and hence reducing the incidence of the disease.

Screening for and vaccination against HBV should be part of routine antenatal care for pregnant women.

ALT and TNF-alpha estimation should be introduced during pregnancy to reduce the risk of obstetric complications.

Our result underscores the need for molecular identification and characterization of the virus and to determine the relationship between the viral load and the immune response (TNF-alpha levels), level of liver damage (ALT levels) with viremia and to determine the pattern of distribution and the rate of transmission to infants at birth.

CONSENT

As per international standard or university standard, patient's written consent

has been collected and preserved by the authors.

ETHICAL APPROVAL

As per international standard or university standard, written approval of Ethics committee has been collected and preserved by the authors.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: Mar-15. World Health Organization; 2015.
2. Saidu AY, Salihu Y, Umar AA, Muhammad BS, Abdullahi I. Seroprevalence of hepatitis B surface antigen among pregnant women attending ante-natal clinics in Sokoto Metropolis; 2015.
3. Akani CI, Ojule AC, Oporum HC, Ejilemele AA. Sero-prevalence of hepatitis B surface antigen (HBsAg) in pregnant women in Port Harcourt, Nigeria. The Nigerian Postgraduate Medical Journal. 2005; 12(4):266-70.
4. Saleh RH, Hadi BH. Correlation between the prevalence of hepatitis B and C viruses against tumor necrosis factor- α among patients in Babylon province. Br Microbiol Res J. 2016;12:1-0.
5. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF- α) agents for rheumatic and dermatologic conditions: A systematic review and meta-analysis. International Journal of Rheumatology. 2014;2014.
6. Hunt CM, Sharara AI. Liver disease in pregnancy. American Family Physician. 1999;59:829-43.
7. Acq Y. The liver in normal pregnancy; 2013.
8. Hunt CM, Sharara AI. Liver disease in pregnancy. American Family Physician. 1999;59:829-43.
9. Everson GT. Liver problems in pregnancy: Distinguishing normal from abnormal

- hepatic changes. *Medscape Women's Health*. 1998;3(2):3.
10. Everson GT. Liver problems in pregnancy: part 2--managing pre-existing and pregnancy-induced liver disease. *Medscape Women's Health*. 1998;3(2):2.
 11. Oladeinde BH, Omoregie R, Oladeinde OB. Prevalence of HIV, HBV, and HCV infections among pregnant women receiving antenatal care in a traditional birth home in Benin City, Nigeria. *Prevalence*. 2013;2(2):113-7.
 12. Eke AC, Eke UA, Okafor CI, Ezebialu IU, Ogbuagu C. Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. *Virology Journal*. 2011;8(1):12.
 13. Centers for Disease Control and Prevention (CDC). Screening for chronic hepatitis B among Asian/Pacific Islander populations--New York City, 2005. *MMWR. Morbidity and mortality weekly report*. 2006;55(18):505. However, perinatally acquired HBV is a largely preventable condition (Vu-Lam, et.al., 2010).
 14. Lam NC, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. *Am Fam Physician*. 2010; 82(10):1225-9.
 15. Sadoh AE, Eregie CO. Age at presentation for infant immunization in Nigeria: implications for hepatitis B immunization. *Public health*. 2008;122(12):1318-20.
 16. Vitoratos N, Economou E, Iavazzo C, Panoulis K, Creatsas G. Maternal serum levels of TNF-alpha and IL-6 Long after delivery in preeclamptic and normotensive pregnant women. *Mediators of Inflammation*; 2010.
 17. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. *Journal of Medical Microbiology*. 2012;61(7):935-43.
 18. National Population Commission. Federal republic of Nigeria official gazette no 4: 94. Legal Notice on Population of the 2006 Census Report; 2007.
 19. National Population Commission. Report of Nigeria's National Population Commission on the 2006 Census; 2006.
 20. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. *Journal of Hepatology*. 2007;47(4):598-607.
 21. Thrushfield M. Surveys; In *Veterinary epidemiology*. 3rd Ed. Blackwell Science Ltd., Oxford, England. 2007;228–246.
 22. Ndako JA, Echeonwu GO, Nwankiti OO, Onovoh EM, Jah AU, Shidali NN, Ikani PA. Sero-survey of hepatitis B surface antigen amongst pregnant women attending Infectious Disease Hospital Bayara, Bauchi State, Nigeria. *Microbiology Research*. 2012;3(1):10.
 23. Baba MM, Onwuka IS, Baba SS. Hepatitis B and C infections among pregnant women in Maiduguri, Nigeria. *Central European Journal of Public Health*. 1999; 7(2):60-62.
 24. Ndako JA, Onwuliri FC, Banda JM, Alejolowo OO, Fajobi V, Olapade DO. Risk factors and prevalence of hepatitis B surface antigen (HBsAg) among apparently healthy volunteers in an Urban Setting, North-Central Nigeria. *International Journal of Science*. 2016; 5(3):9-15.
 25. Ndams IS, Joshua IA, Luka SA, Sadiq HO. Epidemiology of hepatitis B infection among pregnant women in Minna, Nigeria. *Science World Journal*. 2008;3(3).
 26. Ezegbudo CN, Igwe CU, Agba MI et al. The seroprevalence of hepatitis B Surface antigen and human immuno deficiency virus among pregnant women in Anambra state Nigeria. *Shir E-Med J*. 2004;5:20-.
 27. Obi SN, Onah HE, Ezugwu FO. Risk factors for hepatitis B infection during pregnancy in a Nigerian obstetric population. *Journal of Obstetrics and Gynaecology*. 2006;26(8):770-2.
 28. Alvarado-Mora MV, Fernandez MF, Gomes-Gouvea MS, Neto RS, Carrihlo FJ, Pinho JR. Hepatitis B, Hepatitis C and Hepatitis D viruses in the colombian population - how is the epidemiological situation? *Public Library of Science One* 6; 2011.
 29. WHO/EPI. Protocol for Assessing Prevalence of Hepatitis B Infection in Antenatal Patients. WHO/EPI/GEN/90.6; 1990.
 30. Ugbebor O, Aigbirior M, Osazuwa F, Enabudoso E, Zabayo O. The prevalence of hepatitis B and C viral infections among pregnant women. *North American Journal of Medical Sciences*. 2011;3(5):238.
 31. Oladeinde BH, Omoregie R, Oladeinde OB. Prevalence of HIV, HBV, and HCV infections among pregnant women

- receiving antenatal care in a traditional birth home in Benin City, Nigeria. *Prevalence*. 2013;2(2):113-7.
32. Tsai WL, Chung RT. Viral hepatocarcinogenesis. *Oncogene*. 2010; 29(16):2309.
 33. Zhang H, Li Q, Sun J, Wang C, Gu Q, Feng X, Du B, Wang W, Shi X, Zhang S, Li W. Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. *International Journal of Medical Sciences*. 2011;8(4):321.
 34. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: A prospective study. *British Journal of Cancer*. 1997; 76(7):968.
 35. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS. Taiwan childhood hepatoma study group. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. *JAMA*. 2000; 284(23):3040-2.
 36. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, Moreno-Otero R, Alonso JL, Yague E, Pivel JP, Lopez-Cabrera M, Fernandez-Ruiz E, Sanchez-Madrid F. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. *Journal of Experimental Medicine*. 1994;179(3):841-8.
 37. Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein CI. TNF-induced liver injury. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 1998;275(3):G387-92.
 38. Sabry HS, El-Hendy AA, Mohammed HI, Essa AS, Abdel-Aziz AS. Study of serum tumor necrosis factor- α in patients with liver cirrhosis. *Menoufia Medical Journal*. 2015;28(2):525.
 39. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C. Serum levels of cytokines in chronic liver disease. *Gastroenterology*. 2002;103:264-274.
 40. Bilgic Y, Harputluoglu M, Yaprak B, Bozan MB, Sahin A, Yazar FM, Cagin YF, Okcu N. The relationship between hepatic activity index and serum tumor necrosis factor alpha levels in patients with chronic active hepatitis-B and chronic active Hepatitis-C. *Medicine Science*. 2015; 4(4):2772-2781.
 41. Nagaki M, Iwai H, Naiki T, Ohnishi H, Muto Y, Moriwaki H. High levels of serum interleukin-10 and tumor necrosis factor- α are associated with fatality in fulminant hepatitis. *The Journal of Infectious Diseases*. 2000;182(4):1103-8.
 42. Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein CI. TNF-induced liver injury. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 1998;275(3):G387-92.

© 2018 Rabiu et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

*The peer review history for this paper can be accessed here:
<http://www.sciencedomain.org/review-history/23968>*